Abstract:Background: The recent pandemic of obesity and the metabolic syndrome (MetS) has led to the realisation that new drug targets are needed to either reduce obesity or the subsequent pathophysiological consequences associated with excess weight gain. Certain nuclear hormone receptors (NRs) play a pivotal role in lipid and carbohydrate metabolism and have been highlighted as potential treatments for obesity. This realisation started a search for NR agonists in order to understand and successfully treat MetS and associated conditions such as insulin resistance, dyslipidaemia, hypertension, hypertriglyceridemia, obesity and cardiovascular disease. The most studied NRs for treating metabolic diseases are the peroxisome proliferator-activated receptors (PPARs), PPAR-α, PPAR-γ, and PPAR-δ. However, prolonged PPAR treatment in animal models has led to adverse side effects including increased risk of a number of cancers, but how these receptors change metabolism long term in terms of pathology, despite many beneficial effects shorter term, is not fully understood. In the current study, changes in male Sprague Dawley rat liver caused by dietary treatment with a PPAR-pan (PPAR-α, -γ, and -δ) agonist were profiled by classical toxicology (clinical chemistry) and high throughput metabolomics and lipidomics approaches using mass spectrometry. Results: In order to integrate an extensive set of nine different multivariate metabolic and lipidomics datasets with classical toxicological parameters we developed a hypotheses free, data driven machine learning approach. From the data analysis, we examined how the nine datasets were able to model dose and clinical chemistry results, with the different datasets having very different information content. Conclusions: We found lipidomics (Direct Infusion-Mass Spectrometry) data the most predictive for different dose responses. In addition, associations with the metabolic and lipidomic data with aspartate amino transaminase (AST), a hepatic leakage enzyme to assess organ damage, and albumin, indicative of altered liver synthetic function, were established. Furthermore, by establishing correlations and network connections between eicosanoids, phospholipids and triacylglycerols, we provide evidence that these lipids function as a key link between inflammatory processes and intermediary metabolism.

Recon8D: A metabolic regulome network from oct-omics and machine learning

Recon8D: A metabolic regulome network from oct-omics and machine learning

Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information.

An Ensemble Metabolome-Epigenome Interaction Network Identifies Metabolite Modulators of Epigenetic Drugs

Autonomous Multimodal Metabolomics Data Integration for Comprehensive Pathway Analysis and Systems Biology

MSD-MAP: A Network-Based Systems Biology Platform for Predicting Disease-Metabolite Links

Systematic classification of unknown metabolites using high-resolution fragmentation mass spectra

Machine Learning-Based Integrated Multiomics Characterization of Colorectal Cancer Reveals Distinctive Metabolic Signatures

Pan-Cancer, Genome-Scale Metabolic Network Analysis of over 10,000 Patients Elucidates Relationship between Metabolism and Survival

Multivariate analysis of metabolic state vulnerabilities across diverse cancer contexts reveals synthetically lethal associations

A Comparative Evaluation of Tools to Predict Metabolite Profiles From Microbiome Sequencing Data

Abstract 3512: Joint probabilistic modeling of multimodal metabolic data with UnitedMet

Predicting Enzyme Targets for Cancer Drugs by Profiling Human Metabolic Reactions in NCI-60 Cell Lines

Integration of metabolomics, lipidomics and clinical data using a machine learning method

Prediction of intracellular metabolic states from extracellular metabolomic data

A method to identify high consensus predictions of single-cell metabolic flux

UnitedMet harnesses RNA-metabolite covariation to impute metabolite levels in clinical samples

Stitching Together Multiple Data Dimensions Reveals Interacting Metabolomic and Transcriptomic Networks That Modulate Cell Regulation

Differential metabolic activity and discovery of therapeutic targets using summarized metabolic pathway models

Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data

Identifying Personalized Metabolic Signatures in Breast Cancer